Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers. However, the efficacy of cisplatin treatment is often limited by the development of drug resistance either through the inhibition of apoptotic genes or activation of antiapoptotic genes. We have previously reported the overexpression of human UO-44 (HuUO-44) in ovarian cancers and the HuUO-44 antisera markedly inhibited NIH-OVCAR3 ovarian cancer cell attachment and proliferation (Oncogene 23: 5707-5718, 2004). In the present study, we observed through the cancer cell line profiling array that the expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) after treatment with several chemotherapeutic drugs. Similarly, this suppression in HuUO-44 expression was also correlated to the cisplatin sensitivity in two other ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose-dependent manner. To elucidate the function of HuUO-44 in cisplatin chemoresistance in ovarian cancer cell, small interfering RNAs (siRNAs) were employed to mediate HuUO-44 silencing in ovarian cancer cell line, NIH-OVCAR3. HuUO-44 RNA interference (RNAi) resulted in the inhibition of cell growth and proliferation. Importantly, HuUO-44 RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced by cisplatin (Po0.01). Strikingly, we have also demonstrated that overexpression of HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (Po0.05). Taken together, UO-44 is involved in conferring cisplatin resistance; the described HuUO-44-specific siRNA oligonucleotides that can potently silence HuUO-44 gene expression may prove to be valuable pretreatment targets for antitumor therapy or other pathological conditions that involves aberrant HuUO-44 expression.
Introduction
Despite advances in ovarian cancer treatment in the last 40 years, it remains as the second most common gynecological malignancy (McGuire and Markman, 2003) . Cisplatin is one of the most potent antitumor agents, that are known to display clinical activity against a wide variety of solid tumors, and cisplatin-based treatments have been a standard of care for women diagnosed with advanced epithelial ovarian cancer for more than two decades (Muggia et al., 2000) . Cisplatin belongs to the chemotherapy group of alkylating agents that binds to DNA creating adduct, crosslinks and strand breaks that inhibit DNA replication leading to the activation of several signal-transduction pathways involving ATR, p53, p73 and mitogen-activated protein kinase resulting in the activation of apoptosis (Judson et al., 1999; Siddik, 2003) . The overall clinical response rate with cisplatin is about 67% and its failure is often associated with significant neurotoxicity, ototoxicity, nephrotoxicity and gastrointestinal as well as myelosuppression (Muggia et al., 2000; McGuire and Markman, 2003) . Other new drugs including paclitaxel, docetaxel, vinorelbine, irinotecan and gemcitabine are currently being used in combination to cisplatin to achieve better survival rates. However, the limited efficacy of cytotoxic chemotherapy remains a key obstacle for the treatment of patients with advanced ovarian cancer. This considerable toxicity observed in patients receiving cisplatin in combination with palitaxel, thus prompted the development of novel therapeutic options, particularly those that employ a combinational approach that targets genes involved in apoptosis and tumor progression.
Advances in the field of gene downregulation using RNA interference (RNAi), through the introduction of small interfering double-stranded RNAs (siRNAs) into cells, can effectively suppress gene expression by mRNA degradation or inhibition of translation (Ryther et al., 2005; Tebes and Kruk, 2005) . Silencing of several targets using siRNA has already been reported to cause growth suppression of various cancer cell lines and is therefore a promising approach for gene therapy (Ryther et al., 2005; Devi, 2006) . However, owing to the involvement of numerous genes in tumor progression, simultaneous inhibition of multiple target genes may be necessary to effectively inhibit tumor progression. It is therefore necessary to combine the use of siRNA with other compounds, such as chemotherapeutic agents, to elicit the synergistic antineoplastic effects in tumors.
In fact, a few siRNAs have already been shown to enhance sensitivity to different chemotherapeutic drugs in vitro (Cioca et al., 2003; July et al., 2004) . For instance, silencing various targets in ovarian cancer including Her-2/neu can result in in vitro decreased cell proliferation, increased apoptosis, increased G0/G1 arrest and decreased tumor growth (Yang et al., 2004) . Likewise, H-ras RNAi resulted in decreased ovarian tumor growth and ovarian cancer cell line transformation efficiencies (Yang et al., 2003 (Yang et al., , 2004 Choudhury et al., 2004) . Similarly, targeting heparin-binding EGFlike growth factor (HB-EGF) with siRNA also resulted in decreased tumor growth in ovarian cancer cell lines (Menendez et al., 2004) . In addition, siRNA targeting genes that confer multidrug resistance, p-gp and GST, has also been previously shown to restore cisplatin sensitivity in vitro (Duan et al., 2004) . Correspondingly, inhibition of ABCB1 and ABCB4 gene by siRNA has also been shown to sensitize ovarian cancer cells to paclitaxel (Miyamoto et al., 2004) . Given the success of RNAi in several in vivo studies as well as the promising data from gynecologic malignancies in tissue culture and animal studies, it is only a matter of time before RNAi enters the realm of clinical therapeutics either as a therapeutic agent or a chemosensitizing agent for treatment of gynecological and/or other types of cancers.
UO-44 (also known as CUZD1) encoded for a transmembrane-associated protein that is first cloned from a pregnant mouse uterus complementary DNA (cDNA) library (Kasik, 1998) and is expressed in the uterus and ovaries (Huynh et al., 2001) . Primary translation product of the UO-44 gene encodes a polypeptide of 607 amino acids, which contains a secretory signal sequence, two CUB domains, a zona pellucida domain and a transmembrane region (Chen et al., 1999) . UO-44 has been implicated in diverse physiological functions, including pregnancy development (Kasik, 1998; Chen et al., 1999) , protection against severity of pancreatitis (Imamura et al., 2002) and cell adhesion (Huynh et al., 2001 ). In our previous study, we have isolated alternatively spliced variants of the human UO-44 gene, which may function to regulate its gene expression (Leong et al., 2004) . Another feature of UO-44 is its overexpression in a majority of ovarian tumors, suggesting that the gene exerts a significant role in tumorigenesis and progression of ovarian cancers (Leong et al., 2004) .
In general, UO-44 expression is upregulated in the uterus during cell proliferation induced by estrogens but downregulated during cell stress by pure anti-estrogen (ICI 182780) (Chen et al., 1999; Huynh et al., 2001) . More specifically, the human orthologue of UO-44 (HuUO-44) is involved in ovarian cancer cell attachment and proliferation (Leong et al., 2004) . Collectively, these previous findings identify that UO-44 functions in ovarian cancer cell invasiveness, and silencing of UO-44 may enhance cell death following treatment with chemotherapeutic agents. In the present study, we discovered that cisplatin treatment resulted in the downregulation of HuUO-44 expression and report for the first time that silencing of HuUO-44 using sequencespecific siRNAs resulted in the significant enhanced cisplatin sensitivity in human ovarian cancer cells (NIH-OVCAR3). Additionally, we have also demonstrated that overexpression of HuUO-44 in NIH-OVCAR3 cells conferred resistance to cisplatin chemotherapy.
Results
Human UO-44 expression using the cell line profiling array Effect of chemotherapeutic treatment on HuUO-44 expression in cancer cell lines was investigated using the cancer cell line profiling array. There were no significant differences in HuUO-44 expression in the treated lung, colon, breast, prostate, skin, brain, kidney, liver, bone and epidermis cancer cell lines (data not shown). Only the ovarian cancer cell line (SKOV3) showed a reduction in HuUO-44 expression after treatment with geldanamycin, aphidicoline, carmustine, cisplatin, L-mimosine and demecolcine by a magnitude of more than onefold of the control (Figure 1) . Treatment with hydroxyurea, cytochalasine D, doxorubicin, desferrioxamine, camptothecin, mitomycine, Taxol, thiotepa, hydrogen peroxide and gamma irradiation observed only a half-fold reduction in HuUO-44 expression. Serum starvation, UV irradiation, heat shock, cycloheximide, actinomycin D, etoposide and 5-fluorouracil treatments did not show any significant effect on HuUO-44 expression in SKOV-3 cells.
Cytotoxic effect of cisplatin on ovarian cancer cell lines To further investigate the cytotoxic effect of chemotherapeutic drugs on ovarian cancer cell lines, four different ovarian cancer cell lines were treated with cisplatin using doses ranging from 0 to 26.7 mM for 48 h and the dimethylthiazol-2-yl 2-5-diphenyltetrazolium bromide (MTT) assay was used to determine cell viability (Figure 2 ). NIH-OVCAR3 was found to be most sensitive to cisplatin, followed by SKOV-3, OV-90 and ES-2 cells. Rounding of NIH-OVCAR3 cells was observed 48 h post-treatment with 3.3 mM of cisplatin, whereas the same phenomenon was only observed in OV-90 and SKOV-3 when treated with 6.7 mM of cisplatin. The cytotoxic effect of cisplatin was less pronounced in ES-2, as only very few rounded-up cells were observed after treatment with cisplatin concentrations as high as 26.7 mM.
Effect of cisplatin on HuUO-44 expression in ovarian cancer cell lines Semiquantitative one-step reverse transcription-polymerase chain reaction (RT-PCR) demonstrated that the dose-dependent inhibition of cell viability by cisplatin was correlated with the suppression of HuUO-44 expression in NIH-OVCAR3, SKOV3 and OV-90 (Figure 3a) . For the cisplatin-resistant ES-2 cell line, the levels of HuUO-44 expression were the same as that in the untreated cells. Quantitative real-time PCR was employed to determine the magnitude of this cisplatinregulated suppression in HuUO-44 expression in NIH-OVCAR3 cells, and we observed a transcript reduction of more than 90% with 26.7 mM cisplatin treatment ( Figure 3b ). Figure 3c presents the phase-contrast micrograph of the NIH-OVCAR3 cells treated for 48 h with varying concentrations of cisplatin (0-26.7 mM).
Sequence-specific, dose-dependent suppression of HuUO-44 by siRNA To further demonstrate the involvement of HuUO-44 in cancer cell attachment and proliferation, we proceed to silence the gene in NIH-OVCAR3 cell. Three siRNAs of different target sequences (Table 1) were transfected into the cells daily for 2 days. siRNA U1 was designed to silence only the full-length HuUO-44D (GenBank accession number AY260047); siRNA U2 targeted the silencing of variants HuUO-44B (GenBank accession number AY260049), HuUO-44C (GenBank accession number AY260048) and HuUO-44D, and siRNA U3 targeted the silencing of all HuUO-44 transcripts.
Using semiquantitative one-step RT-PCR, it was found that siRNA U3 was the most efficient in silencing the HuUO-44 gene expression. Combined transfection of all the siRNAs (U1-3) containing one-third of each siRNA also gave a similar level of silencing ( Figure 4a ). These findings were confirmed with real-time PCR analysis, which demonstrated that the HuUO-44 siRNAs contributed to 17, 35, 69 and 74% of HuUO-44 transcript silencing when NIHOVCAR-3 cells were transfected with siRNA U1, U2, U3 and a combination of all three HuUO-44 siRNAs, respectively ( Figure 4b ). Transfection with siRNA U1 did not exert any significant effect on HuUO-44 expression and no HuUO-44 siRNAs enhances cisplatin sensitivity in vitro CTC Leong et al Enhanced chemosensitivity in vitro after silencing of To determine whether silencing of HuUO-44 can enhance the cytotoxic effect of cisplatin, NIH-OVCAR3 cells were transfected with 100 nM of HuUO-44 siRNAs and the medium GC control siRNA twice, once for 6 h followed by recovery for 18 h in growth media and once 3 h before cisplatin (3.3 mM) treatment for 12 h. Percentages of apoptotic cells were determined using flow cytometry after fluorescent staining with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (Figure 6a ). The percentages of early and late apoptotic cells after 12 h cisplatin treatment were plotted against the untreated cells (Figure 6b ). Knockdown of HuUO-44 by siRNA significantly enhanced cisplatin sensitivity in NIH-OVCAR3 cells (Po0.05), increasing the percentage of apoptotic cells by more than 50% compared to the Med GC control siRNAtransfected cells. Figure 6c presents the phase-contrast micrographs of the above siRNAs transfected and cisplatin-treated NIH-OVCAR3 cells. HuUO-44 RNAi also resulted in enhanced efficacy of cisplatin, requiring only 12 h treatment with 3.3 mM cisplatin to cause cell rounding compared to 48 h treatment as shown in the cisplatin cytotoxicity assay (Figure 2) .
Expression of HuUO-44 conferred resistance to cisplatin
To determine whether overexpression of HuUO-44 can confer resistance to cisplatin, the cisplatin-sensitive NIH-OVCAR3 cells were transfected with a mammalian expression vector containing the open-reading frame (ORF) of HuUO-44. Two stable transfectant clones expressing low and high levels of HuUO-44 were selected ( Figure 7a ) and treated with 3.3 mM cisplatin for 18 h. Percentages of apoptotic cells were quantitated using flow cytometry after fluorescent staining with Annexin V-FITC and PI (Figure 7b) . The percentages of cell death after 18 h cisplatin treatment were plotted against the untreated cells (Figure 7c) .
Expression of high levels of HuUO-44 significantly enhanced cisplatin resistance in NIH-OVCAR3 cells with a fivefold increase in the percentage of cell death compared to the control stable clone containing the pcDNA3 vector (Po0.05). Rounding of the pcDNA3 stable transfectants was observed after 18 h of cisplatin treatment, this phenomenon was also observed in the HuUO-44 stable transfectant, HuUO-44(1), which overexpressed about fourfold more HuUO-44 transcript compared to the control (Figure 7d ). Strikingly, treatment with cisplatin only resulted in a few rounded cells in the other HuUO-44 stable transfectant, HuUO-44 siRNAs enhances cisplatin sensitivity in vitro CTC Leong et al , which overexpressed more than 40-fold of HuUO-44 transcript compared to the pcDNA3 control transfectants.
Discussion
Chemotherapy has been regarded as a standard therapy for the majority of women with advanced epithelial ovarian cancer for several decades (McGuire and Markman, 2003) . Chemoresistance could be developed through the alterations in apoptotic machinery, activation of antiapoptotic pathways or expression of antiapoptotic genes (Siddik, 2003) . Agents like cisplatin that are used to destroy malignant cells may therefore also induce expression of genes that mediate chemoresistance. Our present study investigates the involvement of HuUO-44 in chemoresistance. UO-44 is an inscrutable protein that is overexpressed in the pancreas, uterus and ovaries (Huynh et al., 2001; Leong et al., 2004) . Despite previous in vitro and in vivo studies, which reflect its multifunctionality, its common function remains unclear. We have previously shown that the HuUO-44 is upregulated in a majority of ovarian cancers and have demonstrated that HuUO-44 is involved in ovarian cancer cell attachment and proliferation (Leong et al., 2004) . Our presented data clearly demonstrated that the regulation of HuUO-44 expression was related with the chemoresistance of ovarian cancer cells. Our first clue relating HuUO-44 to chemoresistance in ovarian cancer cell lines was provided by the observation that HuUO-44 expression was suppressed in SKOV-3 cells treated with various chemotherapeutic agents with cytotoxic mode of action involving DNA damage. In agreement, our further investigation on the toxicity of cisplatin in four ovarian cancer cell lines revealed that the sensitivity to cisplatin was correlated to the reduction in HuUO-44 expression. The expression of HuUO-44 was seemingly strictly related to the cell exposure to apoptosis-inducing agents and may therefore be related to the main HuUO-44 function under physiological conditions. Similarly, according to a series of studies in UO-44 À/À mice, it was shown that UO-44 increased the susceptibility to severity of secretagogue and diet-induced pancreatitis compared to the UO-44 þ / þ mice. Further investigation observed that the acinar cells had an increased susceptibility to apoptotic cell death in the UO-44-deficient animals (Imamura et al., 2002) . 
HuUO-44 siRNAs enhances cisplatin sensitivity in vitro CTC Leong et al
The ability of 21-nucleotide duplexes of siRNA to direct sequence-specific degradation of mRNA (Tuschl et al., 1999; Harborth et al., 2001) , causing gene-specific silencing in mammalian cells, has provided us with a rapid method for UO-44 functional analysis or to modulate gene expression in human disease. Our present study represents the first report of the use of siRNA to silence the HuUO-44 gene. We have previously isolated four novel spliced variants of HuUO-44 and discussed its role in regulation of its gene expression (Leong et al., 2004) . More specifically, the three HuUO-44 siRNAs, U1, U2 and U3, were designed to target HuUO-44 exon 2, exon 4 and exon 6. Silencing of these individual exons demonstrated the sequence-specific silencing of the different variants, which contributed to the varying levels of HuUO-44 gene silencing.
Furthermore, the dose-dependent silencing of HuUO-44 through siRNAs in ovarian cancer cell line, NIH-OVCAR3, demonstrated a decline in cell growth through the inhibition of cell attachment (Figure 5b ). This detachment of epithelial cells from an extracellular matrix results in a form of apoptosis known as anoikis (Frisch and Francis, 1994) . This same phenomenon was also observed in another ovarian cancer cell line, SKOV3, when transfected with varying concentrations of siRNA (Supplementary Figure) . However, no knockdown of HuUO-44 expression was observed in OV-90 when transfected with HuUO-44 siRNAs and no morphological change was observed (data not shown). A possible reason for this could be the lower transfection efficiency of this cell line, which could severely affect the delivery of the siRNAs. Strikingly, we have HuUO-44 siRNAs enhances cisplatin sensitivity in vitro CTC Leong et al also found that HuUO-44 RNAi chemosensitized human NIH-OVCAR3 ovarian cancer cells in vitro ( Figure 6 ). Consistent with the above RNAi studies, the overexpression of HuUO-44 conferred resistance to cisplatin in ovarian cancer cells (Figure 7 ). These findings illustrated that HuUO-44 is involved in conferring cisplatin resistance in ovarian cancer cells and HuUO-44 RNAi significantly increased the efficacy of cisplatin treatment. The reduced growth in the HuUO-44 knockdown cell line was most probably related to the progressive loss of ability of the cells to adhere to a substrate and cisplatin further activated DNA damage-mediated signal-transduction pathways that culminated in the activation of apoptosis.
In summary, our data demonstrated that the oligonucleotide-induced suppression of HuUO-44 expression intensifies apoptosis and significantly enhances chemosensitivity (Po0.01). Coherent to this finding, the overexpression of HuUO-44 in ovarian cancer cell significantly conferred resistance to cisplatin (Po0.05). Based on our previous observation that HuUO-44 is overexpressed in a majority of ovarian cancers and ovarian cancer cell lines, our present experimental findings support the development of target strategies employing HuUO-44 siRNAs to complement the conventional cytotoxic therapies for advance ovarian cancers.
Materials and methods

Cancer cell line profiling array
The probe used in the cancer cell line profiling array was radioactively labeled with [a-
32 P]deoxy-CTP (Perkin-Elmer, 
Treatment of cells with cisplatin
Cisplatin stock of 1 mg/ml was purchased from Mayne Pharma Plc, Warwickshire, UK. The stock solution was diluted with growth medium to the required concentrations (in mM) before each in vitro experiment.
SiRNA for RNAi of UO-44
Invitrogen Life Technologies Inc. Carlsbad, CA, USA supplied all the HuUO-44-specific siRNAs. The sequence of the siRNAs listed in Table 1 corresponded to the HuUO-44 (CUZD1) cDNA sequence (GenBank accession number AY260047 and NM_022034). The Stealth RNAi Negative Control Med GC that has no homology to the vertebrate transcriptome was used as a negative control.
Transfection of siRNA Transfection of HuUO-44 siRNA U1, U2, U3 and the negative control was performed using Lipofectamine 2000 (Invitrogen). Cells were seeded the day before siRNA transfection in six-well plates and were 50-60% confluent during transfection. The RNA duplex was diluted in sterile water and 100 nM of the siRNA duplex was used in each transfection mixture. NIH-OVCAR3 cells were treated with the siRNA after 20 min preincubation with 5 ml of Lipofectamine 2000 in serum-free OPTI-MEM (Invitrogen). When cells were transfected with all three HuUO-44 siRNAs, one-third of each siRNA duplex was used. Six hours after transfection, the medium was replaced with RPMI culture medium described above. Transfection of siRNA was performed daily for 2 consecutive days, then harvested 24 h following the final transfection.
Cytotoxicity assay
In vitro cytotoxicity assays were performed using the MTT(Sigma Chemical Co, St Louis, MO, USA) assay. Cells were seeded into 48-well plates at 4 Â 10 4 cells/well and were treated with different doses of cisplatin ranging from 0 to 53.3 mM. After 48 h of treatment, 40 ml of 10 mg/ml MTT reagent and 200 ml of serum-free media was added to each well and incubated in the dark for 4 h at 371C. Formazan crystals were dissolved in the SDS-DMF solution, which contained 0.7 M SDS (Bio-Rad, Laboratories Inc., Hercules, CA, USA) in 50% N,N-dimethylformamide (Sigma) at pH 4.3. After dissolving the resulting formazan product, the absorbance was determined with a Benchmark Plus Microplate Spectrophotometer (Bio-Rad) at 570 nm. Normalization was performed with the values obtained from the untreated cells to determine the percentage of survival. Each treatment was performed in triplicate.
Semiquantitative RT-PCR and real-time PCR analysis Total RNA was isolated from the four different ovarian cancer cell lines using TRIZOL (Invitrogen) according to the manufacturer's instructions. For the semiquantitative analysis, 1 mg of total RNA was reverse transcribed followed by PCR using the one-step RT-PCR Kit (Qiagen) following the manufacturer's instructions. The primer sequences used for amplification of HuUO-44 mRNA (1520-2158 bp; GenBank accession number AY260047) were 5 0 -CATGGCTCTTTTT GAATCCAATTC-3 0 and 5 0 -GTTAATAGTTCTGCAGC TTCT-3 0 . The cycles chosen for one-step RT-PCR reaction were reverse transcription at 451C for 30 min; activation of Taq polymerase at 951C for 15 min, followed by 30 cycles of 941C for 10 s, 551C for 1 min, 681C for 1 min, and a final extension of 681C for 10 min. The amplified products were separated on a 1.5% agarose gel.
For quantitative real-time PCR analysis, the first strand cDNA was obtained through the reverse transcription of 1 mg of total RNA using SuperScript II Reverse Transcriptase (Invitrogen) according to the manufacturer's instructions. One microliter of the resulting cDNA was used in the subsequent PCR reaction in iQ SYBR Green Supermix (Bio-Rad), with the following cycles: 951C for 3 min, followed by 40 cycles of 951C for 10 s; 581C for 30 s and 721C for 30 s. MyiQ real-time PCR Detection System (Bio-Rad) was used to monitor realtime the PCR amplification, and the DNA concentration of each reaction was determined quantitatively using a standard curve. For both semiquantitative and quantitative gene expression analysis, a-tubulin was used as a reference gene to normalize the differences in the amount of total RNA and to compensate for different RT efficiencies. Sequence for the a-tubulin primers were 5 0 -AACGTCAAGACGGCCGTGT-3 0 and 5 0 -GACAGAGGCAAACTGAGCAC-3 0 . Agarose gel electrophoresis and melt curve analysis were used to confirm the absence of nonspecific amplification products.
Apoptosis assay
Externalization of phosphatidylserine (PS) was examined with a two-color analysis of FITC-labeled Annexin V binding and PI uptake flow cytometry (Vermes et al., 1995) . For this analysis, 1 Â 10 6 cells were stained using the commercially available kit, Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences Pharmingen, San Diego, CA, USA) according to the manufacturer's instructions.
Cell debris was characterized by a low forward scatter/side scatter and was excluded from the analysis. Single stained cells either with FITC-Annexin V or PI were used to adjust compensation. Fluorescence was quantified using FL1 and FL2 channels of the FACSCalibur flow cytometer (BD Biosciences); data acquisition and analysis were carried out using the CellQuest s software (BD Biosciences). Positioning of quadrants on Annexin V/PI dot plots was performed based on a previous report (van Engeland et al., 1996) Generation and transfection of HuUO-44 constructs Amplification of HuUO-44 FL ORF of 1824 bp was achieved using the following primers: HuUO-44/F (5 0 -CACCATGC CATTGACCCTCTTAATT-3 0 ) and HuUO-44/R (5 0 -GTTAA TAGTTCTGCAGCTTCT-3 0 ). PCR was performed using a plasmid containing the transcript HuUO-44D (GenBank accession number. AY260047) as template, in a total volume of 50 ml containing 10 pmol of each primer, 100 nmol of each dNTP, 1 IU of native Pfu polymerase (Stratagene, La Jolla, CA, USA), 1.5 mM MgCl 2 and 1 Â Native Pfu Buffer (Stratagene). The following cycles were used for PCR: 951C for 5 min, followed by 25 cycles of 951C for 30 min, 551C for 30 min, 721C for 1 min 30 s, and a final extension of 721C for 5 min. The resulting PCR product was subsequently cloned into pCR-Blunt-II-TOPO vector (Invitrogen) and subcloned directionally into a pcDNA3 (Invitrogen) mammalian expression vector via HindIII and NotI restriction enzyme sites found on both vectors.
After sequence verification of the HuUO-44FL-ORFpcDNA3.0 constructs, a maxi-prep of the construct was prepared using the Endofree Plasmid Maxi Kit (Qiagen). Before the day of transfection, 5 Â 10 6 NIH-OVCAR3 cells were seeded onto a 100 mm tissue culture dish. The plate was about 70% confluent during transfection; 10 mg of HuUO-44FL-pcDNA3.0 or pcDNA3.0 plasmids was transfected into the NIH-OVCAR3 cells after 20 min preincubation with 10 ml of Lipofectamine 2000 (Invitrogen) in serum-free OPTI-MEM (Invitrogen). The transfection mix was replaced with growth medium, 6 h after transfection. After a further 12 h of incubation, the transfected cells were trypsinized and selected in growth medium containing Geneticin-G418 (Invitrogen) for 3 weeks. Single colonies of stable transfectants were then isolated and assayed for HuUO-44 expression using real-time PCR analysis.
Statistical analysis
All experiments were repeated at least three times and the data were subjected to Student's unpaired t-test. For all statistical tests, significance was established at Po0.05.
